Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2018
Revised process for ultra-orphan medicines
8 October 2018 - Following the Scottish Government's announcement around a new pathway in June 2018, a new approach to the ...
Posted by Michael Wonder on 18 Sep 2018
Changes to TGA/PBAC parallel processing arrangements for biosimilar medicines
18 September 2018 - Submissions requesting the listing of a new biosimilar medicine are no longer eligible to be submitted under ...
Posted by Michael Wonder on 03 Sep 2018
Biosimilar awareness initiative – literature review
3 September 2018 - The biosimilar literature review update for the period March 2018 to May 2018 is now available. ...
Posted by Michael Wonder on 31 Aug 2018
Medicines Australia welcomes announcement LSDP Expert Panel
31 August 2018 - Medicines Australia welcomes today’s announcement by Minister for Health, the Hon Greg Hunt MP on the ...
Posted by Michael Wonder on 27 Jun 2018
New from CADTH: procedural guidelines and a streamlined therapeutic review framework
27 June 2018 - Recent changes continue to strengthen the Pharmaceutical Reviews portfolio and help CADTH adapt quickly to the changing ...
Posted by Michael Wonder on 27 Apr 2018
What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews
27 April 2018 - Finch assessed the evidence on the validity and responsiveness of five commonly used preference-based instruments, the ...
Posted by Michael Wonder on 22 Apr 2018
The Australian Managed Entry Scheme: are we getting it right?
23 April 2018 - In 2010, the Australian Government introduced the managed entry scheme (MES) to improve patient access to subsidised ...
Posted by Michael Wonder on 27 Mar 2018
Gene therapy: international regulatory and health technology assessment activities and reimbursement status
28 March 2018 - There is widespread variation in the definition of gene therapy used by international regulatory bodies and a ...
Posted by Michael Wonder on 27 Mar 2018
Revamp national cancer, mental health groups, panel tells minister
27 March 2018 - Dramatic overhaul urged to role of Ottawa and its arm's-length organizations in health care. ...
Posted by Michael Wonder on 19 Mar 2018
Funding breakthrough therapies: a systematic review and recommendation
17 March 2018 - Advanced therapy medicinal products are innovative therapies likely associated with high prices. ...
Posted by Michael Wonder on 11 Mar 2018
The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the pan-Canadian Oncology Drug Review 2011–2017
20 January 2018 - Most Canadian provinces and territories rely on the pan-Canadian Oncology Drug Review to provide recommendations regarding public ...
Posted by Michael Wonder on 01 Feb 2018
Advance notice of consultation about changes to the Pharmaceutical Schedule Rules
1 February 2018 - PHARMAC is working to make the Pharmaceutical Schedule Rules easier to find, use and apply. ...
Posted by Michael Wonder on 31 Jan 2018
Health policy reform not helped by Bill Shorten
31 January 2018 - It is noteworthy that shares in Medibank Private hit a record high the day after Opposition ...
Posted by Michael Wonder on 29 Jan 2018
Rare disease medicine changes offer clarity
29 January 2018 - Proposed changes to the provision of medicines for rare diseases should bring greater certainty for people ...
Posted by Michael Wonder on 29 Jan 2018
Medicines Australia welcomes LSDP review outcomes
28 January 2018 - Medicines Australia welcomes the Government’s announcement of an outcome from the post-market review of the Life ...